GIST Support International - logo

GIST Support International - RDEA119
GIST Imagery


RDEA119 is an orally administered inhibitor of MEK, downstream from RAS in the MAPK pathway.  It inhibits cell proliferation by arresting dividing cells in the G1 phase of the cell cycle. 

NCI drug dictionary definition: RDEA119 is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor RDEA119 specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

manufacturer: Ardea Biosciences, Inc. See their website
For information on RDEA119 at the Ardea website link here.

Clinical Trials relevant to GIST:
RDEA119 and Sorafenib Combination Dose Escalation Study

This trial may be particularly relevant to patients with NF1 GIST, which has strong activation of the MAPK pathways.  It might also be relevant to the few GIST patients with wildtype KIT and BRAF mutations.

An abstract of an ASCO 2008 Molecular Markers meeting presentation is available:
The effect of MEK inhibitor RDEA119 on biomarkers in advanced cancer patients in a phase I clinical trial

Several posters about RDEA119 presented at recent cancer meetings are available in pdf format:

The Effect of MEK Inhibitor RDEA119 on Biomarkers in Advanced Cancer Patients in a Phase 1 Clinical Trial

RDEA119: A Potent and Highly Selective MEK Inhibitor for the Treatment of Cancer

Design and Synthesis of RDEA119 a Potent and Orally Bioavailable MEK Inhibitor

back to top